Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia

Br J Haematol. 2018 Oct;183(2):168. doi: 10.1111/bjh.15432. Epub 2018 Jul 5.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Benzoates / administration & dosage
  • Benzoates / therapeutic use
  • Dose-Response Relationship, Drug
  • Female
  • Hematologic Agents / administration & dosage
  • Hematologic Agents / therapeutic use*
  • Humans
  • Hydrazines / administration & dosage
  • Hydrazines / therapeutic use
  • Middle Aged
  • Platelet Count
  • Purpura, Thrombocytopenic, Idiopathic / blood
  • Purpura, Thrombocytopenic, Idiopathic / drug therapy*
  • Pyrazoles / administration & dosage
  • Pyrazoles / therapeutic use
  • Receptors, Fc / administration & dosage
  • Receptors, Fc / therapeutic use
  • Receptors, Thrombopoietin / agonists*
  • Recombinant Fusion Proteins / administration & dosage
  • Recombinant Fusion Proteins / therapeutic use
  • Thiazoles / administration & dosage
  • Thiazoles / therapeutic use
  • Thiophenes / administration & dosage
  • Thiophenes / therapeutic use
  • Thrombopoietin / administration & dosage
  • Thrombopoietin / therapeutic use
  • Treatment Outcome

Substances

  • Benzoates
  • Hematologic Agents
  • Hydrazines
  • Pyrazoles
  • Receptors, Fc
  • Receptors, Thrombopoietin
  • Recombinant Fusion Proteins
  • Thiazoles
  • Thiophenes
  • avatrombopag
  • Thrombopoietin
  • romiplostim
  • eltrombopag